Canaccord analyst William Plovanic raised the firm’s price target on iRhythm to $143 from $135 and keeps a Buy rating on the shares. The analyst said it seems the company has already seen solid traction in its next area of growth, the primary care segment, including announcing a nationwide agreement with One Medical and some other unnamed primary care networks.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IRTC:
- iRhythm Sees FY23 revenue $475M-$485M, consensus $485.6M
- iRhythm reports Q4 EPS (67c), consensus (62c)
- iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results
- iRhythm Technologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- iRhythm initiated with an Overweight at Wells Fargo
